Widely used:Recently Viewed
Clear All
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
$430 Mln
P/E Ratio
--
P/B Ratio
2.46
Industry P/E
--
Debt to Equity
0.28
ROE
-0.29 %
ROCE
-23.14 %
Div. Yield
0 %
Book Value
3.59
EPS
-1.15
CFO
$-1,667.37 Mln
EBITDA
$-1,738.41 Mln
Net Profit
$-1,972.77 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Theravance Biopharma (TBPH)
| -8.40 | -6.61 | 2.13 | -11.04 | -4.61 | -19.86 | -7.40 |
|
BSE Sensex
| 0.39 | 6.40 | 1.96 | 7.69 | 10.43 | 20.75 | 10.61 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
|
|---|---|---|---|---|---|---|---|
|
Theravance Biopharma (TBPH)
| 0.18 | 1.54 | -37.82 | -31.36 | 1.17 | -8.20 | -12.52 |
|
S&P Small-Cap 600
| 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 | 11.73 |
|
BSE Sensex
| 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 | 27.91 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes of medicines in the United States. It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary... disease (COPD). The company's product includes Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; and TRELEGY for the treatment of COPD and asthma. It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California. Address: 901 Gateway Boulevard, South San Francisco, CA, United States, 94080 Read more
Chairman & CEO
Mr. Rick E. Winningham M.B.A.
Chairman & CEO
Mr. Rick E. Winningham M.B.A.
Headquarters
South San Francisco, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Theravance Biopharma Inc (TBPH) stood at $ 354 Mln as on 31-Dec-24
The share price of Theravance Biopharma Inc (TBPH) is $8.62 (NASDAQ) as of 17-Apr-2025 16:00 EDT. Theravance Biopharma Inc (TBPH) has given a return of -4.61% in the last 3 years.
Theravance Biopharma Inc (TBPH) has a market capitalisation of $ 430 Mln as on 17-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Theravance Biopharma Inc (TBPH) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Theravance Biopharma Inc (TBPH) and enter the required number of quantities and click on buy to purchase the shares of Theravance Biopharma Inc (TBPH).
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes of medicines in the United States. It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). The company's product includes Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; and TRELEGY for the treatment of COPD and asthma. It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California. Address: 901 Gateway Boulevard, South San Francisco, CA, United States, 94080
The CEO & director of Mr. Rick E. Winningham M.B.A.. is Theravance Biopharma Inc (TBPH), and CFO & Sr. VP is Mr. Rick E. Winningham M.B.A..
There is no promoter pledging in Theravance Biopharma Inc (TBPH).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|
| Theravance Biopharma Inc. (TBPH) | Ratios |
|---|---|
|
Return on equity(%)
|
-29.04
|
|
Operating margin(%)
|
-73.25
|
|
Net Margin(%)
|
-87.63
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Theravance Biopharma Inc (TBPH) was $0 Mln.
$0.03
(
